Ablynx

Technologiepark 21

9052 Zwijnaarde

BE

Ablynx

Foundation date

2001

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.

Upcoming events

Latest news

  • Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017

    22 hours ago

  • eTheRNA immunotherapies appoints Mathieu Lane as Chief Financial Officer and President of eTheRNA Inc. located in the U.S.A

    1 day ago

  • Allegro inaugrates new lab at Bluechem

    1 day ago